February 1st 2023
Health care expert and lived experience panels came to a consensus on several aspects that should be considered in the decision to offer and continue active surveillance for prostate cancer.
FDA Approves Darolutamide Combo for Metastatic Hormone-Sensitive Prostate Cancer
August 9th 2022Darolutamide, sold as Nubeqa, is an androgen receptor inhibitor, which works to limit prostate cell growth by preventing the binding of hormones, or androgens, to proteins known as androgen receptors.
Read More
Dr Ashley Ross on the Potential for Targeted Therapies Earlier in Prostate Cancer Treatment
February 3rd 2021Ashley Ross, MD, urologist and associate professor at the Northwestern University Feinberg School of Medicine, gives insight on the potential for PARP inhibitors in earlier disease settings for prostate cancer.
Read More
Study Finds Shorter Radiation Regimen Safe, Effective for Advanced Prostate Cancer
January 30th 2021Shortening a traditional 45-day course of radiation therapy to 5 days of stereotactic body radiotherapy for patients with advanced, high-risk prostate cancer is safe and effective, a study from UCLA Jonsson Comprehensive Cancer Center found.
Read More
Congress passes legislation that will delay the start of the Radiation Oncology (RO) Advanced Payment Model; examining the newly identified variant of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19); a study finds Hispanics and those without college degrees most subject to excess death during pandemic.
Read More